| NCT ID | NCT06525831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Kidney Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-03-07 |
| Primary Completion | 2027-05-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-03-07 with a primary completion date of 2027-05-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this innovative project is to evaluate the correspondence between several imaging modalities for characterizing the elasticity of healthy and pathological renal tissue which could help improve the realism of 3D prints used by urological surgeons and allow the identification of new, complementary imaging biomarkers. The main objective is to develop a predictive model of the biomechanical properties of normal and pathological kidney tissue, as assessed by the reference method (Magnetic Resonance (MR)-elastography).
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years of age) * Scheduled for surgical management with nephrectomy for kidney tumor in the urology department of Bordeaux University Hospital * CT scan available or scheduled for surgery * Consent expressed for integration of the UroCCR database * Expressed consent for participation in the Rein 3D Print Mechanics study * Patients affiliated or benefiting from social security system Exclusion Criteria: * \- Pregnant or breast-feeding women * Contraindication to MRI (Magnetic Resonance Imaging) * Contraindication to injection of gadoline contrast agents * Biopsy performed within 15 days prior to MRI, CT and ultrasound scans (risk of artifactual alteration, via iatrogenic hemorrhagic changes, of the biomechanical properties of the renal tumor and parenchyma). * Presence of thoracolumbar arthrodesis material * Obese patient (body mass index ≥ 30 kg/m²) * Cystic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm * Necrotic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm * Ascites * Person under legal protection * Difficulty understanding and expressing in French
Contact & Investigator
FOURAGE EVA, Dr
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT06525831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06525831 currently recruiting?
Yes, NCT06525831 is actively recruiting participants. Contact the research team at eva.fourage@chu-bordeaux.fr for enrollment information.
Where is the NCT06525831 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06525831 clinical trial?
NCT06525831 is sponsored by University Hospital, Bordeaux. The principal investigator is FOURAGE EVA, Dr at University Hospital, Bordeaux. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.